RT Journal Article
SR Electronic
T1 Clinical trial emulation can identify new opportunities to enhance the regulation of drug safety in pregnancy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.12.21266269
DO 10.1101/2021.11.12.21266269
A1 Challa, Anup P.
A1 Niu, Xinnan
A1 Garrison, Etoi A.
A1 Van Driest, Sara L.
A1 Bastarache, Lisa M.
A1 Lippmann, Ethan S.
A1 Lavieri, Robert R.
A1 Goldstein, Jeffery A.
A1 Aronoff, David M.
YR 2021
UL http://medrxiv.org/content/early/2021/11/14/2021.11.12.21266269.abstract
AB From the perspective of most regulatory agencies, it is usually unethical to perform interventional clinical trials on pregnant people. While this policy recognizes the vulnerability of an expectant mother and unborn child, it has created a public health emergency for millions of pregnant patients through a dearth of robust safety data for many common drugs. To address this problem, we harnessed an enterprise collection of 2.8M electronic health records (EHRs) originally collected from routine primary care, leveraging the data linkage between mothers and their babies to create a surrogate for randomized, controlled drug trials in this population. To demonstrate the feasibility of our clinical trial emulation platform to stimulate new hypotheses for post-market drug surveillance, we identified 1,054 drugs historically prescribed to pregnant patients and developed a medication history-wide association study and follow-up evidence synthesis platform—leveraging expert clinician review and real-world data analysis—to test the effects of maternal exposure to these drugs on the incidence of neurodevelopmental defects in their children. Our results replicate known teratogenic risks and existing knowledge on drug structure-related teratogenic risks. Herein, we highlight 5 common drug classes that we believe warrant further assessment of their safety in pregnancy. We also discuss our efforts to develop a discovery-to-regulatory framework that could allow for pragmatic translation of our results to enhanced regulatory policy. Collectively, our work presents a simple approach to evaluating the utility of EHRs in guiding new regulatory review programs focused on improving the delicate equipoise of accuracy and ethics inherent to assessing drug safety in an extremely vulnerable patient population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAPC, DMA, and EAG acknowledge support from award R21HD105304 from National Institute of Child Health and Development (NICHD) of NIH. APC, DMA, and ESL also acknowledge relevant funding from award U54TR02243-02 from National Center for Advancing Translational Sciences (NCATS) of NIH. APC and DMA are additionally funded for a study of therapeutic index in pregnancy by award N009367701 from Rainwater Charitable Foundation. SLV was supported by IRSA #1015006 from the Burroughs Wellcome Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) of Vanderbilt University approved the research that we describe below as exempt from human subjects research (IRB #191553).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDisclosure of our MedWAS data, though de-identified and aggregated, is subject to approval and oversight by the Office of Contracts Management (OCM) at VUMC, as our source data is derived from protected health information (PHI), and some drug-disease pairs are individually identifiable. Therefore, institutional policies prevent us from publicly releasing our data tables and their annotations, but, within the data sharing regulations of our institution, we have attempted to provide meaningful information on the content and formatting of our outputs throughout this manuscript. We are committed to open-source science and to ensuring the reproducibility of the research we present here; therefore, we are happy to discuss data transfer requests with researchers interested in our results. Interested investigators should contact the Corresponding Authors at the addresses accompanying this manuscript, and they are happy to discuss forwarding such requests to OCM.ATCAnatomical Therapeutic ChemicalCDMcommon data modelCDSclinical decision supportEHRelectronic health recordFDAUnited States Food and Drug AdministrationICDInternational Classification of DiseaseIRBinstitutional review boardKMCIKnowledgeMap concept identifierMedWASmedication history-wide association studyMLmachine-learningNCATSNational Center for Advancing Translational SciencesNICHDNational Institute of Child Health and DevelopmentNIHUnited States National Institutes of HealthNLPnatural language processingOCMOffice of Contracts ManagementORodds ratioOTCover-the-counterPheWASphenome-wide association studyPSpropensity scoringRCTrandomized, controlled trialRDResearch DerivativeRWEreal-world evidenceVUMCVanderbilt University Medical Center